Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07003191Active Not Recruiting

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Role: collaborator

NCT04150835Phase 4Unknown

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Role: collaborator

NCT02728180Phase 4Unknown

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Role: collaborator

All 3 trials loaded